Tenascin-W is a novel marker for activated tumor stroma in low-grade human breast cancer and influences cell behavior

Cancer Research

Volumn 67, Issue 19, 2007, Pages 9169-9179

  Degen, Martin ^a   Brellier, Florence ^a   Kain, Renate ^c   Ruiz, Christian ^b   Terracciano, Luigi ^b   Orend, Gertraud ^b   Chiquet Ehrismann, Ruth ^a  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; COMPLEMENTARY DNA; FIBRONECTIN; SCLEROPROTEIN; TENASCIN; TENASCIN W; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4; VERY LATE ACTIVATION ANTIGEN 5;

ARTICLE; BREAST; BREAST CANCER; CANCER GRADING; CELL FUNCTION; CELL SPECIFICITY; DIAGNOSTIC VALUE; DNA MICROARRAY; FIBROBLAST; FROZEN SECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FAMILY; REGULATORY MECHANISM; WESTERN BLOTTING;

BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; FIBROBLASTS; FIBRONECTINS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM STAGING; STROMAL CELLS; TENASCIN; TUMOR MARKERS, BIOLOGICAL;

EID: 35148851502     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0666     Document Type: Article

References (51)

1. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer 2001;1:46-54.
2. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003;3:422-33.
3. Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004;4:839-49.
4. Beacham DA, Cukierman E. Stromagenesis: the changing face of fibroblastic microenvironments during tumor progression. Semin Cancer Biol 2005;15:329-41.
5. Bhowmick NA, Moses HL. Tumor-stroma interactions. Curr Opin Genet Dev 2005;15:97-101.
6. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6:392-401.
7. Joesting MS, Perrin S, Elenbaas B, et al. Identification of SFRP1 as a candidate mediator of stromal-toepithelial signaling in prostate cancer. Cancer Res 2005;65:10423-30.
8. Yang F, Tuxhorn JA, Ressler SJ, McAlhany SJ, Dang TD, Rowley DR. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res 2005;65:8887-95.
9. Cruz-Munoz W, Kim I, Khokha R. TIMP-3 deficiency in the host, but not in the tumor, enhances tumor growth and angiogenesis. Oncogene 2005;26:650-5.
10. Hill R, Song Y, Cardiff RD, Van Dyke T. Selective evolution of stromalmesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 2005;123:1001-11.
11. Kammertoens T, Schuler T, Blankenstein T. Immunotherapy: target the stroma to hit the tumor. Trends Mol Med 2005;11:225-31.
12. Lee J, Fassnacht M, Nair S, Boczkowski D, Gilboa E. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer Res 2005;65:11156-63.
13. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375-9.
14. Chiquet-Ehrismann R, Mackie EJ, Pearson CA, Sakakura T. Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell 1986;47:131-9.
15. Orend G. Potential oncogenic action of tenascin-Cin tumorigenesis. Int J Biochem Cell Biol 2005;37:1066-83.
16. Chiquet-Ehrismann R, Chiquet M. Tenascins: regulation and putative functions during pathological stress. J Pathol 2003;200:488-99.
17. Jones FS, Jones PL. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn 2000;218:235-59.
18. Zagzag D, Friedlander DR, Dosik J, et al. Tenascin-C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro. Cancer Res 1996;56:182-9.
19. Schnyder B, Semadeni RO, Fischer RW, et al. Distribution pattern of tenascin-C in normal and neoplastic mesenchymal tissues. Int J Cancer 1997;72:217-24.
20. Miller DW, Vosseler S, Mirancea N, et al. Rapid vessel regression, protease inhibition, and stromal normalization upon short-term vascular endothelial growth factor receptor 2 inhibition in skin carcinoma heterotransplants. Am J Pathol 2005;167:1389-403.
21. Zagzag D, Capo V. Angiogenesis in the central nervous system: a role for vascular endothelial growth factor/vascular permeability factor and tenascin-C. Common molecular effectors in cerebral neoplastic and non-neoplastic "angiogenic diseases." Histol Histopathol 2002;17:301-21.
22. Huang W, Chiquet-Ehrismann R, Moyano JV, Garcia-Pardo A, Orend G. Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. Cancer Res 2001;61:8586-94.
23. Ruiz C, Huang W, Hegi ME, et al. Growth promoting signaling by tenascin-C[corrected]. Cancer Res 2004;64:7377-85.
24. Scherberich A, Tucker RP, Degen M, Brown-Luedi M, Andres AC, Chiquet-Ehrismann R. Tenascin-W is found in malignant mammary tumors, promotes α8 integrin-dependent motility and requires p38MAPK activity for BMP-2 and TNF-α induced expression in vitro. Oncogene 2005;24:1525-32.
25. Lange K, Kammerer M, Hegi M, et al. Endothelin receptor type B counteracts tenascin-C-induced endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization. Cancer Res 2007;67:6163-73.
26. Schenk S, Muser J, Vollmer G, Chiquet-Ehrismann R. Tenascin-C in serum: a questionable tumor marker. Int J Cancer 1995;61:443-9.
27. Schoenberg Fejzo M, Slamon DJ. Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, proteins. Am J Pathol 2001;159:1645-50.
28. Schreiner CL, Bauer JS, Danilov YN, Hussein S, Sczekan MM, Juliano RL. Isolation and characterization of Chinese hamster ovary cell variants deficient in the expression of fibronectin receptor. J Cell Biol 1989;109:3157-67.
29. 1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell 1990;60:849-59.
30. 4 subunit in the upper face of the β-propeller mode 1. Proc Natl Acad Sci U S A 1997;94:7198-203.
31. 1 integrin functions as a fibronectin receptor but does not support fibronectin matrix assembly and cell migration on fibronectin. J Cell Biol 1993;122:235-42.
32. Tucker R, Drabikowski K, Hess J, Ferralli J, Chiquet-Ehrismann R, Adams J. Phylogenetic analysis of the tenascin gene family: evidence of origin early in the chordate lineage. BMCevo lutionary biology 2006;6:60.
33. Borsi L, Carnemolla B, Nicolo G, Spina B, Tanara G, Zardi L. Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer 1992;52:688-92.
34. Orend G, Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett 2006;244:143-63.
35. van't Veer L, Dau H, van de Vijver M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:484-5.
36. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6.
37. Farmer P, Bonnefoi H, Becette V, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005;24:4660-71.
38. Chiquet-Ehrismann R. Tenascins, a growing family of extracellular matrix proteins. Experientia 1995;51:853-62.
39. Norenberg U, Wille H, Wolff JM, Frank R, Rathjen FG. The chicken neural extracellular matrix molecule restrictin: similarity with EGF-, fibronectin type III-, and fibrinogen-like motifs. Neuron 1992;8:849-63.
40. Ikuta T, Sogawa N, Ariga H, Ikemura T, Matsumoto K. Structural analysis of mouse tenascin-X: evolutionary aspects of reduplication of FNIII repeats in the tenascin gene family. Gene 1998;217:1-13.
41. von Holst A, Egbers U, Prochiantz A, Faissner A. Neural stem/progenitor cells express 20 tenascin C isoforms that are differentially regulated by pax6. J Biol Chem 2007;282:9172-81.
42. Meiners S, Nur-e-Kamal MS, Mercado ML. Identification of a neurite outgrowth-promoting motif within the alternatively spliced region of human tenascin-C. J Neurosci 2001;21:7215-25.
43. Meiners S, Geller HM. Long and short splice variants of human tenascin differentially regulate neurite outgrowth. Mol Cell Neurosci 1997;10:100-16.
44. Fischer D, Tucker RP, Chiquet-Ehrismann R, Adams JC. Cell-adhesive responses to tenascin-C splice variants involve formation of fascin microspikes. Mol Biol Cell 1997;8:2055-75.
45. Weber P, Montag D, Schachner M, Bernhardt RR. Zebrafish tenascin-W, a new member of the tenascin family. J Neurobiol 1998;35:1-16.
46. Scherberich A, Tucker RP, Samandari E, Brown-Luedi M, Martin D, Chiquet-Ehrismann R. Murine tenascin-W: a novel mammalian tenascin expressed in kidney and at sites of bone and smooth muscle development. J Cell Sci 2004;117:571-81.
47. Meloty-Kapella CV, Degen M, Chiquet-Ehrismann R, Tucker RP. Avian tenascin-W: expression in smooth muscle and bone, and effects on calvarial cell spreading and adhesion in vitro. Dev Dyn 2006;235:1532-42.
48. Adams M, Jones JL, Walker RA, Pringle JH, Bell SC. Changes in tenascin-C isoform expression in invasive and preinvasive breast disease. Cancer Res 2002;62:3289-97.
49. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
50. Tanaka K, Hiraiwa N, Hashimoto H, Yamazaki Y, Kusakabe M. Tenascin-Cregulates angiogenesis in tumor through the regulation of vascular endothelial growth factor expression. Int J Cancer 2004;108:31-40.
51. Ballard VL, Sharma A, Duignan I, et al. Vascular tenascin-Cregulates cardiac endothelial phenotype and neovascularization. Faseb J 2006;20:717-9.